Multiple pathways contribute to the pathogenesis of Huntington disease

被引:90
作者
Li, Shihua [1 ]
Li, Xiao-Jiang [1 ]
机构
[1] Emory Univ, Dept Human Genet, Sch Med, Atlanta, GA 30322 USA
关键词
D O I
10.1186/1750-1326-1-19
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington disease (HD) is caused by expansion of a polyglutamine (polyQ) domain in the protein known as huntingtin (htt), and the disease is characterized by selective neurodegeneration. Expansion of the polyQ domain is not exclusive to HD, but occurs in eight other inherited neurodegenerative disorders that show distinct neuropathology. Yet in spite of the clear genetic defects and associated neurodegeneration seen with all the polyQ diseases, their pathogenesis remains elusive. The present review focuses on HD, outlining the effects of mutant htt in the nucleus and neuronal processes as well as the role of cell-cell interactions in HD pathology. The widespread expression and localization of mutant htt and its interactions with a variety of proteins suggest that mutant htt engages multiple pathogenic pathways. Understanding these pathways will help us to elucidate the pathogenesis of HD and to target therapies effectively.
引用
收藏
页数:10
相关论文
共 148 条
[1]   THE RELATIONSHIP BETWEEN TRINUCLEOTIDE (CAG) REPEAT LENGTH AND CLINICAL-FEATURES OF HUNTINGTONS-DISEASE [J].
ANDREW, SE ;
GOLDBERG, YP ;
KREMER, B ;
TELENIUS, H ;
THEILMANN, J ;
ADAM, S ;
STARR, E ;
SQUITIERI, F ;
LIN, BY ;
KALCHMAN, MA ;
GRAHAM, RK ;
HAYDEN, MR .
NATURE GENETICS, 1993, 4 (04) :398-403
[2]  
[Anonymous], 1991, HUNTINGTONS DIS
[3]   Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death [J].
Arrasate, M ;
Mitra, S ;
Schweitzer, ES ;
Segal, MR ;
Finkbeiner, S .
NATURE, 2004, 431 (7010) :805-810
[4]   p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease [J].
Bae, BI ;
Xu, H ;
Igarashi, S ;
Fujimuro, M ;
Agrawal, N ;
Taya, Y ;
Hayward, SD ;
Moran, TH ;
Montell, C ;
Ross, CA ;
Snyder, SH ;
Sawa, A .
NEURON, 2005, 47 (01) :29-41
[5]  
BEAL MF, 1994, NEUROBIOL AGING, V15, P275
[6]   Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation [J].
Behrens, P. F. ;
Franz, P. ;
Woodman, B. ;
Lindenberg, K. S. ;
Landwehrmeyer, G. B. .
BRAIN, 2002, 125 :1908-1922
[7]   Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease [J].
Benn, CL ;
Landles, C ;
Li, H ;
Strand, AD ;
Woodman, B ;
Sathasivam, K ;
Li, SH ;
Ghazi-Noori, S ;
Hockly, E ;
Faruque, SMNN ;
Cha, JHJ ;
Sharpe, PT ;
Olson, JM ;
Li, XJ ;
Bates, GP .
HUMAN MOLECULAR GENETICS, 2005, 14 (20) :3065-3078
[8]   Huntington's disease:: from huntingtin function and dysfunction to therapeutic strategies [J].
Borrell-Pages, M. ;
Zala, D. ;
Humbert, S. ;
Saudou, F. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (22) :2642-2660
[9]   Histone deacetylase inhibitors as therapeutics for polyglutamine disorders [J].
Butler, Rachel ;
Bates, Gillian P. .
NATURE REVIEWS NEUROSCIENCE, 2006, 7 (10) :784-796
[10]   Loss of normal huntingtin function: new developments in Huntington's disease research [J].
Cattaneo, E ;
Rigamonti, D ;
Goffredo, D ;
Zuccato, C ;
Squitieri, F ;
Sipione, S .
TRENDS IN NEUROSCIENCES, 2001, 24 (03) :182-188